16 December 2025
NeuroMetrix, Inc.
10-K / April 30, 2025
NeuroMetrix, Inc. Company Summary
Overview
NeuroMetrix, Inc. is a medical technology company primarily focused on the development and commercialization of neurodiagnostic and neurotherapeutic devices. The company's technology and product development are centered around neurophysiological monitoring and treatment.
Key Details
- Founded: 1996 by Shai N. Gozani, M.D., Ph.D.
- Headquarters: Woburn, Massachusetts
- Principal Offices Address: 4B Gill Street, Woburn, MA 01801
- Telephone: (781) 890-9989
Stock and Market
- Stock Exchange: Nasdaq Stock Market
- Common Stock Par Value: $0.0001 per share
- Number of Shares Outstanding (as of March 28, 2025): 2,059,693 shares
- Market Capitalization (as of June 28, 2024): approximately $6.9 million
Shareholders
- Major non-affiliate beneficial owner: The Radoff Family Foundation holds approximately 203,500 shares (about 9.9%).
Employees
- The document does not specify the number of employees.
Revenue and Income
- The detailed financial results, including revenue and net income for the fiscal year ending December 31, 2024, are not provided in this document.
Business Focus
- NeuroMetrix designs and markets medical devices for neurological monitoring and pain management.
- Its primary revenue focus has been on systems for nerve evaluation and nerve stimulation, targeting patients with neurological and chronic pain conditions.
- The company has engaged in product development to expand its offerings in neurodiagnostics and neurotherapeutics.
Customer Base
- The document does not specify the number of customers served or user demographics.
Summary
NeuroMetrix is a Nasdaq-listed medical technology firm with a focus on neurophysiological diagnostic and therapeutic devices. As of March 2025, it had just over 2 million shares outstanding, with a market value of around $6.9 million. The company was founded in 1996, led by its founder and CEO Shai Gozani, and has a small public market capitalization reflecting a niche focus in neurodiagnostic and neurotherapeutic medical devices. The document does not provide specific financial figures, customer counts, or revenue and income details.
